Buradasınız

Cross sectional study of anaemia in chronic kidney disease

Journal Name:

Publication Year:

Abstract (2. Language): 
Introduction: Chronic kidney disease encompasses a spectrum of different pathophysiological processes associated with progressive decline in glomerular filtration rate. Prevalence of CKD ranges from 0.79% to 1.4%. Kidneys disease is ranked 3rd amongst life threatening diseases in India, after cancer and heart disease. Anemia affects 60-80% of patients with renal impairment and common in both pre-dialysis and on dialysis leading to decreased exercise tolerance, reduced quality of life and additional risk factor for early death. Materials and Methods: 50 cases of CKD were randomly selected for this cross sectional study between October 2012 to August 2014. All patients were examined and investigated thoroughly as per the proforma. Results: The most common type of anemia was NNA with 33(66%) patients. MHA 9(18%) patients and NHA 8(16%) patients mean Hb% was 8.49±1.17 gm%. Most common symptoms were facial puffiness, 44(88%) patients easy fatiguability 39(78%) patients, pedal edema 36(72%), and decreased urine output 21(42%) patients. Most common associated diseases were hypertension 43(86%), diabetes mellitus 32(64%), ischaemic heart disease 14(28%) and dyslipidemia 7(14%). 40 patients were on dialysis and 10 patients were on medical line treatment. Conclusion: CKD is more prevalent in adult population with male predominance in older age groups. Anaemia is the most common complication of CKD and severity of anemia increases as CKD worsens and all patients had anemia. Both MHD and medical line treatment with rEPO have beneficiary effects on Hb% levels.
414
419

REFERENCES

References: 

1. Gupta S, Uppal B, Pawar B. Is soluble transferrin receptor a good marker of iron
deficiency anemia in chronic kidney disease patients? Ind J Nephrol 2009
Jul;19(3):96-99.
2. National Kidney Foundation: Kidney Disease outcomes quality initiative: clinical
pract ice guidelines for anemia of chronic kidney disease. IV NKF-K/DOQI. Update
2000. Am J Kidney Dis 2001;37:S182-238.
Indian Journal of Basic and Applied Medical Research; March 2015: Vol.-4, Issue- 2, P. 414-419
419
www.ijbamr.com P ISSN: 2250-284X , E ISSN : 2250-2858
3. Strippoli GFM, Craig JC, Manno C, Schena FP. Hemoglobin targets for the anemia of
chronic kidney disease: A meta-analysis of randomized, controlled trials. J Am
SocNephrol 2004;15:3154-65.
4. National Kidney Foundation- DOQI Clinical Practice Guidelines on Chronic Kidney
Disease. Executive summary. Am J Kidney Dis 2002; 39 (2) suppl 1: S18.
5. Chug K, Sakhujavi V. Tropical glomerulopathies. Medicine Int 1991;86:3548.
6. Talwar UK, Gupta HL, Narayana S. Clinical haematological profile in chronic renal
failure. J Assoc Physicians India 2002 Feb;50:228-33.
7. Caster V, Bessler H, Malachi T, Zevin D, Djaldetti M, Levi J. Platelet count and
thrombopoit ic act ivi ty in chronic renal failure. Nephron 1987;45:2007-10.
8. Avasthi G, Mittal D, Soni GL. Lipid profile of pat ients of chronic renal failure.
Indian J Med Res 1986;84:612-6.
9. Alam SM, Bhatt AK. Abnormal lipoprotein in uraemic patients treated conservatively
and by maintenance hemodialysis. JAPI 1991;39(2): 170-1.
10. Basha SA, Singh DS, Kotiyal JP, Bisht DB. Study of lipid profile and alimentary
lipemia in chronic renal failure. J AssocPhys India 1979;27:1079-83.
11. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, et al. The Use of
subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of
severe, resistant congestive heart failure improves cardiac and renal function and
functional cardiac class, and markedly reduces hospitalizations. JACC
2000;35(7):1737-44.
12. Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, et al.
Ferumoxytol for treating iron deficiency anemia in CKD. J Am SocNephrol
2008;19:1599-605.
13. Callen IR, Limarzi LR. Blood and bone marrow studies in renal disease. Am J
ClinPathol 1950; 20: 3-23.

Thank you for copying data from http://www.arastirmax.com